Latest news
First patient dosed in the fimaCHEM Phase I extension study
Oslo, 11 August 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the first patient has been dosed in the fimaCHEM Phase I extension study with the objective to evaluate safety and tolerability of repeated treatments with fimaCHEM in patients with inoperable perihilar bile duct cancer. A Phase I study, […]
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Oslo (Norway), 10 July 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over six months, until the end of 2017, and may be further extended. The […]
Interview about fimaCHEM at the Medica Trade Fair homepage 2017
An interview with Prof. Dr. med. Jörg Trojan about treatment of bile duct cancer and the fimaCHEM technology has been published at the Medica Trade Fair homepage. Prof Trojan is Head of Gastrointestinal Oncology at the Cancer Centre at the University Hospital Frankfurt and one of the investigators in the fimaCHEM Phase I study in bile […]